Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1–3 node-positive rapidly proliferating breast cancer

By Amadori Dino   Silvestrini Rosella   Lena Mario   Boccardo Francesco   Rocca Andrea   Scarpi Emanuela   Schittulli Francesco   Brandi Mario   Maltoni Roberta   Serra Patrizia   Ponzone Riccardo   Biglia Nicoletta   Gianni Lorenzo   Tienghi Amelia   Valerio Maria   Bonginelli Paola   Amaducci Laura   Faedi Marina   Baldini Editta   Paradiso Angelo  

Breast Cancer Research and Treatment, Vol. 125, Iss. 3, 2011-02 ,pp. : 775-784

Springer Publishing Company

Access to resources Recommend Favorite

Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: Indirect comparison of dose and schedule in DBCG trials 77, 82, and 89

By Ejlertsen Bent   Mouridsen Henning   Jensen Maj-Britt  

Acta Oncologica, Vol. 47, Iss. 4, 2008-01 ,pp. : 662-671

Informa Healthcare

Access to resources Recommend Favorite

Adjuvant Cyclophosphamide, Methotrexate, Fluorouracil (CMF) in Breast Cancer: Is it Cost-effective?

By Norum Jan  

Acta Oncologica, Vol. 39, Iss. 1, 2000-04 ,pp. : 33-39

Informa Healthcare

Access to resources Recommend Favorite

Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF)

By Batey M.A.   Wright J.G.   Azzabi A.   Newell D.R.   Lind M.J.   Calvert A.H.   Boddy A.V.  

European Journal of Cancer, Vol. 38, Iss. 8, 2002-05 ,pp. : 1081-1089

Elsevier

Access to resources Recommend Favorite

Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of ‘cures’

By demicheli R.  

Breast Cancer Research and Treatment, Vol. 53, Iss. 3, 1999-02 ,pp. : 209-215

Springer Publishing Company

Access to resources Recommend Favorite